Paul Choi
Stock Analyst at Goldman Sachs
(3.84)
# 614
Out of 5,090 analysts
114
Total ratings
54.05%
Success rate
9.13%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Sell | $44 → $50 | $77.26 | -35.28% | 8 | Nov 5, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $55 → $100 | $73.64 | +35.80% | 7 | Oct 31, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $55 | $41.67 | +31.99% | 2 | Oct 29, 2025 | |
| ARVN Arvinas | Downgrades: Sell | $8 → $6 | $12.79 | -53.09% | 4 | Oct 15, 2025 | |
| LNTH Lantheus Holdings | Downgrades: Neutral | $110 → $77 | $63.30 | +21.64% | 2 | Oct 8, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $23.59 | -15.22% | 1 | Sep 25, 2025 | |
| EXEL Exelixis | Initiates: Buy | $47 | $44.36 | +5.95% | 1 | Sep 17, 2025 | |
| AMRN Amarin Corporation | Maintains: Sell | $7 → $12 | $16.54 | -27.45% | 9 | Jun 25, 2025 | |
| URGN UroGen Pharma | Maintains: Neutral | $16 → $3 | $22.98 | -86.95% | 4 | May 22, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $7 → $8 | $3.33 | +140.24% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $5 | $14.58 | -65.71% | 10 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $52 | $45.01 | +15.53% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $6.50 | +223.08% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $12 | $13.16 | -8.81% | 3 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $3.73 | -19.57% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $12 → $10 | $10.89 | -8.17% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $205.44 | +9.52% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $65.67 | -8.63% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $14.22 | +33.61% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.36 | +335.78% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $400 → $50 | $8.42 | +493.82% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.19 | +2,000.84% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $9.55 | +1,680.10% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $5.30 | +50.94% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $155.51 | -13.19% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $56.90 | +427.24% | 2 | Mar 30, 2020 |
PTC Therapeutics
Nov 5, 2025
Maintains: Sell
Price Target: $44 → $50
Current: $77.26
Upside: -35.28%
BridgeBio Pharma
Oct 31, 2025
Maintains: Buy
Price Target: $55 → $100
Current: $73.64
Upside: +35.80%
Kiniksa Pharmaceuticals International,
Oct 29, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $41.67
Upside: +31.99%
Arvinas
Oct 15, 2025
Downgrades: Sell
Price Target: $8 → $6
Current: $12.79
Upside: -53.09%
Lantheus Holdings
Oct 8, 2025
Downgrades: Neutral
Price Target: $110 → $77
Current: $63.30
Upside: +21.64%
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $23.59
Upside: -15.22%
Exelixis
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $44.36
Upside: +5.95%
Amarin Corporation
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $16.54
Upside: -27.45%
UroGen Pharma
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $22.98
Upside: -86.95%
Gossamer Bio
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $3.33
Upside: +140.24%
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $14.58
Upside: -65.71%
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $45.01
Upside: +15.53%
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $6.50
Upside: +223.08%
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $13.16
Upside: -8.81%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $3.73
Upside: -19.57%
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $10.89
Upside: -8.17%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $205.44
Upside: +9.52%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $65.67
Upside: -8.63%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $14.22
Upside: +33.61%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.36
Upside: +335.78%
Jun 27, 2023
Maintains: Sell
Price Target: $400 → $50
Current: $8.42
Upside: +493.82%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.19
Upside: +2,000.84%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $9.55
Upside: +1,680.10%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $5.30
Upside: +50.94%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $155.51
Upside: -13.19%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $56.90
Upside: +427.24%